Biophytis S.A. (6XB.F)
| Previous Close | 0.0022 |
| Open | 0.0022 |
| Bid | 0.0003 x 0 |
| Ask | 0.0044 x 0 |
| Day's Range | 0.0022 - 0.0022 |
| 52 Week Range | 0.0010 - 0.0347 |
| Volume | |
| Avg. Volume | 16,049 |
| Market Cap | 2.865M |
| Beta (5Y Monthly) | 1.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0300 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIREBiophytis Announces Transfer of ADSs to OTC Market
ADSs delisted from Nasdaq, which will result in meaningful savings ADSs transferred to OTC Pink market; Company will apply to trade on OTCQB market Biophytis remains listed on Euronext Growth Paris as its primary trading market PARIS, FRANCE AND CAMBRIDGE, ...
- ACCESSWIRE
Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program
PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 19, 2024 / Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related ...
- ACCESSWIRE
Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity
IND to be filed with the FDA in the coming weeks PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 18, 2024 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized ...
